← 返回前沿论文

mRNA:一种有前景的癌症免疫治疗平台

英文原题:mRNA: A promising platform for cancer immunotherapy.

PubMed 2023/07/04(内容时间) Adv Drug Deliv Rev Q1 · IF 21(JCR 2025)

研究概要

信使RNA(mRNA)如今已成为治疗多种人类疾病,尤其是恶性肿瘤的强大工具,备受瞩目,这得益于COVID-19疫情期间采用脂质纳米颗粒技术的mRNA疫苗所取得的显著临床成果。

中文摘要

信使RNA(mRNA)如今备受瞩目,作为治疗多种人类疾病尤其是恶性肿瘤的强大工具,这得益于COVID-19疫情期间采用脂质纳米颗粒技术的mRNA疫苗所取得的显著临床成果。近期令人鼓舞的临床前和临床结果集中体现了mRNA及基于纳米制剂的递送技术的进步,凸显了mRNA在癌症免疫治疗中的巨大潜力。mRNA可以以多种治疗模式应用于癌症免疫治疗,包括癌症疫苗、过继性T细胞疗法、治疗性抗体和免疫调节蛋白。本综述全面概述了基于mRNA的治疗方法的现状与前景,包括众多递送策略和治疗策略。

展开英文摘要原文

Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

论文信息

作者
Kong B、Kim Y、Kim EH、Suk JS、Yang Y
第一作者单位
Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.United States
通讯作者单位
Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. Electronic address: ysyang@kist.re.kr.South Korea
文献类型
综述 · 非美国政府资助研究 · 美国 NIH 资助研究
期刊
Advanced drug delivery reviews2023 Aug
原文标识
PubMed 37414361 · DOI 10.1016/j.addr.2023.114993